Invivoscribe supplies PCR master mixes for clonality testing in Wales
- Cardiff and Vale University Health Board
- Wales
- Direct award
- 31 March 2026 to 31 December 2026
Cardiff and Vale University Health Board buys PCR master mixes and reagents from Invivoscribe for B and T cell clonality testing. The All Wales Medical Genomics Service uses the tests to diagnose and monitor blood cancers such as lymphoma. The reagents have to come with validated controls, both clonal and polyclonal, plus a control gene. Invivoscribe also provides technical support.
The contract was awarded directly because changing supplier would mean revalidating and re-accrediting every assay, delaying patient testing. The award was made in December 2025 at £108,316, and the contract runs to December 2026.
Contract ends December 2026
- What
- PCR and molecular diagnostic platforms
- Supplier
- Invivoscribe technologies SARL
- Value
- £108,316
- How it was bought
- Direct award
- Dates and next
- Mar 2026 to Dec 2026